SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Lorbrena

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since November 2018. Full first-line approval granted January 2026.
Why 3/10
Lorbrena is already approved and marketed with no pending PDUFA, pivotal readout, or Advisory Committee in the next ~12 months. The next hard catalyst would be a ruling in the Sun Pharma patent lawsuit (filed Oct 2026), but that has no set date. As an approved drug at a mega-cap company, impactScore defaults to 3.
Actionable Insight NEUTRAL

Lorbrena has no near-term binary catalyst. The next event to watch is the Sun Pharma patent litigation (filed Oct 2026 in Delaware), where a ruling could affect generic entry timing. Separately, watch for any label expansion into ROS1-positive NSCLC or pediatric indications. For Pfizer as a whole, Q3 2026 earnings (just reported Nov 3) and the 2027 revenue outlook are far more material than Lorbrena-specific news.

Price Chart

Loading chart...

Executive Summary

Lorbrena (lorlatinib) is Pfizer's third-generation ALK inhibitor for ALK-positive metastatic non-small cell lung cancer. Originally approved in November 2018 under accelerated approval, the FDA expanded it to full first-line approval in January 2026 based on the Phase 3 CROWN trial. Seven-year CROWN data presented at ASCO 2026 showed 55% of patients alive without progression at 7 years, with median progression-free survival still not reached. Lorbrena is a growing but small part of Pfizer's $62.6B revenue base. Pfizer is defending its patent estate (compound patent to March 2033) against a Sun Pharma generic challenge filed in October 2026. The drug has no near-term binary catalyst, making it a low-impact asset for Pfizer's stock.

How It Works

Lorbrena is a pill that blocks a specific cancer-driving protein called ALK (anaplastic lymphoma kinase). About 3-5% of non-small cell lung cancers have a mutation that keeps ALK switched on, making cancer cells grow. Lorbrena is a third-generation drug designed to be more potent than earlier ALK blockers and to penetrate the brain, where lung cancer often spreads. It also blocks a related protein called ROS1.

Trial Status

The pivotal Phase 3 CROWN trial (NCT03052608) comparing Lorbrena to crizotinib in first-line ALK+ advanced NSCLC has completed enrollment. Seven-year follow-up data were presented at ASCO 2026 (May 29, 2026), showing median PFS not yet reached and a 55% progression-free survival rate at 7 years. The trial continues for long-term follow-up.

The Two-Sided Case

▲ Bull Case4
CROWN trial 7-year data (ASCO 2026) showed 55% of patients alive without progression at 7 years and median PFS not yet reached, arguably the longest PFS ever reported in advanced NSCLC.
FDA expanded Lorbrena to full first-line approval in January 2026, broadening the addressable patient population significantly.
Pfizer previously guided that Lorbrena could exceed $1B in annual sales by 2030, and the drug is growing double-digits (part of Pfizer's oncology growth story).
Compound patent runs to March 2033, and Pfizer is actively defending it against Sun Pharma's generic challenge, which could block generic entry for years.
▼ Bear Case4
Lorbrena is a small product within Pfizer's $62.6B revenue base; even strong sales growth has negligible impact on the stock.
Pfizer faces patent litigation from Sun Pharma (ANDA filed), which could bring generic competition before the compound patent expires in March 2033 if Pfizer loses.
The ALK inhibitor class is competitive (alectinib, brigatinib, ensartinib), and pricing pressure could limit Lorbrena's peak sales.
Pfizer discontinued the 120-count bottle of 25mg Lorbrena in June 2026, a minor operational signal but one that raised supply questions.

Upcoming Catalysts

  • Patent litigation against Sun Pharma (filed Oct 1, 2026 in Delaware District Court) - any ruling on generic ANDA could affect Lorbrena's market exclusivity timeline.
  • Potential label expansion into ROS1-positive NSCLC or pediatric ALK-positive glioma (a prior authorization document suggests pediatric glioma exploration).
  • CROWN trial further long-term follow-up data at future medical meetings.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 9

Hover a chip for the title
1 pfizer.com2 pfizer.com3 accessdata.fda.gov4 news.bloomberglaw.com5 hellopharmacist.com6 reuters.com7 cnbc.com8 en.wikipedia.org9 dataintelo.com